基因编辑市场－全球产业规模、份额、趋势、机会和预测：按产品/服务、技术、应用、最终用户、地区和竞争格局划分，2021-2031年

全球基因编辑市场预计将从 2025 年的 70.8 亿美元大幅成长至 2031 年的 132.3 亿美元，复合年增长率为 10.98%。

此领域利用生物技术对生物体的遗传密码进行精确操控，例如在特定位置进行插入、删除和修饰。推动此领域发展的主要因素是先天性遗传疾病发生率的上升，以及CRISPR-Cas9等技术在非癌症治疗领域（包括罕见疾病）的拓展。这种强劲的发展势头在业界的活跃活动中可见一斑。根据美国基因与细胞治疗学会（ASGCT）统计，截至2024年第一季，全球有超过4000种基因、细胞和RNA疗法正在开发平臺中，这凸显了该领域正迅速从实验研究转向潜在的临床应用。

儘管取得了这些进展，但市场仍面临着与可扩展的治疗级载体生产高成本和製程复杂相关的重大障碍。为确保安全性和有效性所需的复杂生产流程造成了巨大的财务障碍，可能限製商业性可行性和病患取得途径。此外，针对脱靶效应和长期安全性数据的严格法律规范可能会延长核准时间，减缓这些创新治疗方法进入商业市场的速度。

市场驱动因素

CRISPR 和下一代基因编辑技术的进步正在从根本上改变全球基因编辑市场，使其从实验科学走向商业性现实。这些精准的基因组工具从实验室成功研发并获得监管部门核准，即时需要专门的基础设施来验证其临床价值并确保患者能够获得治疗。扩大这些营运规模对于复杂治疗方法的商业性成功至关重要，尤其是那些需要严格身份验证通讯协定的体外治疗。 Vertex Pharmaceuticals 就展现了这项进展。根据 Fierce Pharma 报道，到 2024 年 8 月，该公司将在全球运作超过 35 家获得许可的治疗中心，用于开展新核准的CRISPR 疗法。此类基础设施对于消除先进基因药物交付的物流障碍以及促进其在临床环境中的更广泛应用至关重要。

同时，策略联盟的增加正在推动创新，它将大型製药企业的大规模资本与新兴生物技术公司的专业平台结合。此类合作对于克服高成本以及快速将碱基编辑和先导编辑等​​新型基因编辑技术转化为候选疗法至关重要。一个典型的例子是Regeneron Pharmaceuticals和Mammoth Biosciences于2024年4月达成的合作（Labiotech报告），其中包括1亿美元的预付款，用于开发体内CRISPR疗法。此举标誌着该产业正朝着由雄厚资金支持的下一代递送系统进行策略转型。例如，Biospace在2024年8月报告称，CRISPR Therapeutics持有约19亿美元的现金和有价证券，凸显了其为未来市场成长提供的充足资源。

市场挑战

全球基因编辑市场的主要障碍在于生产可扩展的治疗性载体所需的高昂成本和技术难题。病毒载体的生产需要复杂的生物工艺，且必须满足严格的安全性和有效性标准，这往往导致产量低、营运成本过高。这些生产难题成为瓶颈，阻碍了高效的规模化生产，迫使企业采取不可持续的定价策略来收回研发投资。因此，高昂的生产成本推高了市场价格，使其达到过高的水平，直接限制了患者的合格，降低了产品的普及率，从而限制了商业性可行性。

这些财务障碍已在报销和市场进入方面造成了重大困难。这种经济压力导致保险公司和支付方不愿承担高昂的治疗费用，减缓了市场渗透。据再生医学联盟称，到2024年，新核准基因疗法的批发采购成本将达到每位患者310万美元的峰值，凸显了这些复杂生产需求带来的沉重经济负担。在生产流程变得更加经济高效之前，治疗潜力和经济可行性之间的差距将继续阻碍市场发展向更广泛的商业性领域扩展。

市场趋势

将人工智慧 (AI) 整合到引导 RNA 设计中，正在革新药物研发流程，加速设计出超越天​​然变异能力的蛋白质。这些计算模型能够预测脱靶交互作用，并比人工实验方法更快优化结合特异性，从而缩短开发週期，提高基因编辑工具的准确性。Start-UpsProfluent 正在展示这项技术进步。根据 Fierce Biotech 2024 年 4 月的一篇报导报道，“Profluent 将 LLM 和 CRISPR 相结合，打造开源 AI 基因编辑计画”，该公司成功资金筹措了3500 万美元，用于扩展其旨在创建个性化基因编辑工具的生成式 AI 模型。

同时，基因编辑技术在农业和粮食安全领域的应用日益广泛，显示市场正朝着多元化方向发展，而这主要源自于对气候适应型粮食系统的需求。这一趋势旨在利用精准的基因组编辑技术，开发出具有更强抗病性和更长保质期等改良特性的作物，从而规避与基因改造生物相关的复杂监管规定。 AgFunderNews在2024年8月发布的报告《农业基因编辑投资呈现产业復苏迹象》中指出，支持这一发展趋势的是，该领域的Start-Ups在今年上半年资金筹措了超过1.61亿美元的资金。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球基因编辑市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品/服务（试剂/耗材、系统、软体）分类
  • 依技术（CRISPR、TALEN、ZFN、反义寡核苷酸）
  • 依应用领域（细胞株设计、基因工程、药物发现）
  • 依最终用户（製药公司、生技公司、合约研究组织）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美基因编辑市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲基因编辑市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区基因编辑市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲基因编辑市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲基因编辑市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球基因编辑市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• CRISPR Therapeutics AG
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• GenScript Biotech Corporation
• Agilent Technologies, Inc.
• PerkinElmer Inc.
• Lonza Group Ltd.
• Tecan Trading AG
• Sangamo Therapeutics, Inc.
• Editas Medicine, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Gene Editing Market is projected to expand significantly, rising from USD 7.08 Billion in 2025 to USD 13.23 Billion by 2031, reflecting a compound annual growth rate of 10.98%. This sector involves biotechnological techniques that allow for specific alterations-such as insertions, deletions, or modifications-to an organism's genetic code at precise locations. Growth is largely propelled by the increasing incidence of congenital genetic conditions and the broadening scope of technologies like CRISPR-Cas9 into therapeutic realms beyond cancer, including rare diseases. This strong momentum is evidenced by substantial industry activity; the American Society of Gene & Cell Therapy noted that in the first quarter of 2024, the global development pipeline contained over 4,000 gene, cell, and RNA therapies, highlighting the rapid shift from experimental research to potential clinical applications.

Despite these advancements, the market encounters notable obstacles related to the high expense and complexity involved in manufacturing scalable, therapeutic-grade vectors. The sophisticated production processes necessary to guarantee safety and efficacy create significant financial hurdles, which can restrict commercial viability and patient access. Additionally, rigorous regulatory oversight concerning off-target effects and long-term safety data may extend approval timelines, thereby slowing the pace at which these innovative therapies reach the commercial market.

Market Driver

Progress in CRISPR and next-generation editing technologies is fundamentally transforming the Global Gene Editing Market, moving it from experimental science to commercial reality. The successful advancement of these precise genomic tools from labs to regulatory approval has confirmed their clinical value, creating an immediate need for specialized infrastructure to ensure patient access. Scaling these operations is essential for the commercial success of complex treatments, particularly ex vivo therapies that require strict chain-of-identity protocols. This development is exemplified by Vertex Pharmaceuticals, which, according to Fierce Pharma, had activated over 35 authorized treatment centers worldwide by August 2024 to administer its newly approved CRISPR therapy. Such infrastructure is crucial for removing logistical barriers to delivering advanced genetic medicines, thereby facilitating their wider adoption in clinical practice.

Concurrently, an increase in strategic alliances is driving innovation by merging the substantial capital of major pharmaceutical companies with the specialized platforms of emerging biotech entities. These collaborations are vital for surmounting the high costs of R&D and speeding up the translation of new editing methods, such as base and prime editing, into therapeutic candidates. A prime example occurred in April 2024, when Regeneron Pharmaceuticals partnered with Mammoth Biosciences, as reported by Labiotech, involving a $100 million upfront payment to develop in vivo CRISPR-based therapies. This move signals the industry's strategic shift toward next-generation delivery systems, supported by strong financial backing; for instance, BioSpace reported in August 2024 that CRISPR Therapeutics held approximately $1.9 billion in cash and securities, highlighting the resources available for future market growth.

Market Challenge

A major hurdle restraining the Global Gene Editing Market is the substantial cost and technical difficulty involved in producing scalable, therapeutic-grade vectors. The creation of viral vectors demands complex bioprocesses to meet rigorous safety and efficacy standards, often leading to low yields and excessive operational costs. These manufacturing challenges create bottlenecks that hinder efficient scaling, compelling companies to adopt unsustainable pricing strategies to recoup development investments. Consequently, high production costs result in prohibitive market prices, which directly limit commercial viability by restricting patient eligibility and reducing adoption rates.

The consequences of these financial obstacles are manifest in the difficulties regarding reimbursement and market access. This economic pressure causes tension with insurance providers and payers who are reluctant to fund such costly treatments, thereby retarding market penetration. According to the Alliance for Regenerative Medicine, the wholesale acquisition cost for newly approved gene therapies peaked at $3.1 million per patient in 2024, underscoring the intense economic burden associated with these complex production needs. Until manufacturing processes become more cost-effective, the gap between therapeutic potential and economic practicality will continue to impede the market's expansion into a broader commercial landscape.

Market Trends

The incorporation of Artificial Intelligence into Guide RNA design is revolutionizing the discovery pipeline by facilitating the engineering of proteins that surpass natural variants in capability. These computational models can predict off-target interactions and optimize binding specificity much faster than manual experimental techniques, thereby shortening development timelines and enhancing the precision of editing tools. This technological evolution is illustrated by Profluent, a startup that, according to the Fierce Biotech article 'Profluent combines LLMs and CRISPR for open-source AI gene editing project' from April 2024, secured $35 million to expand its generative AI models aimed at creating bespoke gene editors.

In parallel, the broadening of gene editing applications into agriculture and food security marks a diversification of the market beyond human therapeutics, spurred by the necessity for climate-resilient food systems. This trend targets the development of crops with enhanced traits, such as disease resistance and longer shelf lives, using precise genomic modifications that frequently avoid the complicated regulations associated with transgenic organisms. Confirming this sector's expansion, AgFunderNews reported in August 2024, in their 'Agriculture gene editing investments hint at sector recovery' report, that startups in this specific vertical attracted over $161 million in funding during the first half of the year.

Key Market Players

• CRISPR Therapeutics AG
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• GenScript Biotech Corporation
• Agilent Technologies, Inc.
• PerkinElmer Inc.
• Lonza Group Ltd.
• Tecan Trading AG
• Sangamo Therapeutics, Inc.
• Editas Medicine, Inc.

Report Scope

In this report, the Global Gene Editing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Editing Market, By Product & Service

• Reagents & consumables
• Systems
• Software

Gene Editing Market, By Technology

• CRISPER
• TALEN
• ZFN
• Antisense

Gene Editing Market, By Application

• Cell Line Engineering
• Genetic Engineering
• Drug discovery

Gene Editing Market, By End User

• Pharma
• Biotech
• CROs

Gene Editing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Editing Market.

Available Customizations:

Global Gene Editing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gene Editing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product & Service (Reagents & consumables, Systems, Software)
  • 5.2.2. By Technology (CRISPER, TALEN, ZFN, Antisense)
  • 5.2.3. By Application (Cell Line Engineering, Genetic Engineering, Drug discovery)
  • 5.2.4. By End User (Pharma, Biotech, CROs)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Gene Editing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product & Service
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gene Editing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product & Service
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Gene Editing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product & Service
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Gene Editing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product & Service
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Gene Editing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product & Service
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Gene Editing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product & Service
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Gene Editing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product & Service
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Gene Editing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product & Service
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Gene Editing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product & Service
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Gene Editing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product & Service
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Gene Editing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product & Service
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Gene Editing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product & Service
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Gene Editing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product & Service
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Gene Editing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product & Service
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Gene Editing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product & Service
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Gene Editing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product & Service
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Gene Editing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product & Service
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Gene Editing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product & Service
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Gene Editing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product & Service
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Gene Editing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product & Service
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Gene Editing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product & Service
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Gene Editing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product & Service
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Gene Editing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product & Service
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Gene Editing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product & Service
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Gene Editing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. CRISPR Therapeutics AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Thermo Fisher Scientific, Inc.
• 15.4. GenScript Biotech Corporation
• 15.5. Agilent Technologies, Inc.
• 15.6. PerkinElmer Inc.
• 15.7. Lonza Group Ltd.
• 15.8. Tecan Trading AG
• 15.9. Sangamo Therapeutics, Inc.
• 15.10. Editas Medicine, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer